Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Cibinqo Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Cibinqo Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Cibinqo (abrocitinib tablets) for Boeing commercial members, including initial, continuation, renewal, clinical, safety, specialist, combination-therapy, and quantity-limit requirements.

    Policy Summary
    PayerPrime Therapeutics
    PolicyCibinqo Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, required pretreatment, safety evaluation, and specialist involvement for Cibinqo.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Cibinqo strengths covered
    30 tablets/30 daysQuantity limit per strength
    12 monthsApproval duration
    BSA ≥10%Disease severity threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age 50+
    Cardiovascular risk review
    2Quantity-limit exception pathways

    Coverage Criteria

    Continuation and Renewal Therapy

    Target agents will be approved for renewal when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • If the patient is 50 years of age or older with at least one cardiovascular risk factor (e.g., current or past smoker, high blood pressure, high cholesterol, diabetes mellitus, history of heart attack, family history of coronary heart disease, or extra-articular rheumatoid arthritis), the benefits of use outweigh the risks of major adverse cardiovascular events, thrombosis, and all-cause mortality.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, allergist, or immunologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • ONE of the following concomitant-therapy criteria

      • The patient will not be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, or IL-4 inhibitors).
      • Combination-therapy pathway

        • The patient will be using the requested agent in combination with another immunomodulatory agent.
        • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
        • There is support for combination therapy; a submitted copy of clinical trials, phase III studies, or guidelines is required.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Quantity-Limit Approval Criteria

    The quantity limit for the target agent will be approved when ONE of the following is met:

    ONE of the following approval pathways

    • The requested quantity (dose) does not exceed the program quantity limit.
    • The requested quantity (dose) exceeds the program quantity limit and the request meets one of the qualifying quantity-limit exception pathways above.

    Samples do not independently establish continuation of therapy or qualify the patient for approval. Starting treatment with samples is not approvable, and sample use is excluded from the medication history used to establish an initial-indication pathway.

    The requested agent should not be used in combination with another immunomodulatory agent, including TNF inhibitors, JAK inhibitors, or IL-4 inhibitors, unless the prescribing information for the requested agent does not limit combination use and there is support for combination therapy. A submitted copy of clinical trials, phase III studies, or guidelines is required. Combination use must also comply with all applicable prescribing-information limitations.

    For Cibinqo, contraindicated concomitant therapy includes: Abrilada (adalimumab-afzb); Actemra (tocilizumab); Adalimumab; Adbry (tralokinumab-ldrm); Amjevita (adalimumab-atto); Anzupgo (delgocitinib); Arcalyst (rilonacept); Avsola (infliximab-axxq); Avtozma (tocilizumab-anoh); Benlysta (belimumab); Bimzelx (bimekizumab-bkzx); Cibinqo (abrocitinib); Cimzia (certolizumab); Cinqair (reslizumab); Cosentyx (secukinumab); Cyltezo (adalimumab-adbm); Dupixent (dupilumab); Ebglyss (lebrikizumab-lbkz); Enbrel (etanercept); Entyvio (vedolizumab); Exdensur (depemokimab-ulaa); Fasenra (benralizumab); Hadlima (adalimumab-bwwd); Hulio (adalimumab-fkjp); Humira (adalimumab); Hyrimoz (adalimumab-adaz); Icotyde (icotrokinra); Idacio (adalimumab-aacf); Ilaris (canakinumab); Ilumya (tildrakizumab-asmn); Imuldosa (ustekinumab-srlf); Inflectra (infliximab-dyyb); Infliximab; Kevzara (sarilumab); Kineret (anakinra); Leqselvi (deuruxolitinib); Litfulo (ritlecitinib); Nemluvio (nemolizumab-ilto); Nucala (mepolizumab); Olumiant (baricitinib); Omlyclo (omalizumab-igec); Omvoh (mirikizumab-mrkz); Opzelura (ruxolitinib); Orencia (abatacept); Otezla (apremilast); Otezla XR (apremilast extended-release); Otulfi (ustekinumab-aauz); Pyzchiva (ustekinumab-ttwe); Remicade (infliximab); Renflexis (infliximab-abda); Rhapsido (remibrutinib); Riabni (rituximab-arrx); Rinvoq (upadacitinib); Rituxan (rituximab); Rituxan Hycela (rituximab/hyaluronidase human); Ruxience (rituximab-pvvr); Saphnelo (anifrolumab-fnia); Selarsdi (ustekinumab-aekn); Siliq (brodalumab); Simlandi (adalimumab-ryvk); Simponi (golimumab); Simponi ARIA (golimumab); Skyrizi (risankizumab-rzaa); Sotyktu (deucravacitinib); Spevigo (spesolimab-sbzo) subcutaneous injection; Starjemza (ustekinumab-hmny); Stelara (ustekinumab); Steqeyma (ustekinumab-stba); Taltz (ixekizumab); Tezspire (tezepelumab-ekko); Tofacitinib; Tofidence (tocilizumab-bavi); Tremfya (guselkumab); Truxima (rituximab-abbs); Tyenne (tocilizumab-aazg); Tyruko (natalizumab-sztn); Tysabri (natalizumab); Ustekinumab; Velsipity (etrasimod); Wezlana (ustekinumab-auub); Xeljanz (tofacitinib); Xeljanz XR (tofacitinib extended release); Xolair (omalizumab); Yesintek (ustekinumab-kfce); Yuflyma (adalimumab-aaty); Yusimry (adalimumab-aqvh); Zeposia (ozanimod); and Zymfentra (infliximab-dyyb).

    Clinical Thresholds and Documentation Values

    Body Surface Area Involvement
    ThresholdAt least 10% body-surface-area involvement
    ConditionQualifies as one disease-burden criterion for moderate-to-severe atopic dermatitis
    Alternative severity criteriaDifficult-to-treat sites, EASI ≥16, or IGA ≥3 may also establish disease burden
    Eczema Area and Severity Index
    ThresholdEASI ≥16
    ConditionQualifies as one disease-burden criterion for moderate-to-severe atopic dermatitis
    Alternative severity criteria

    Provider Requirements and Denial Risks

    Prior Authorization

    Initial Prior Authorization Requirements

    Initial prior authorization is required. The requested agent may qualify through a continuation-of-therapy pathway or an initial-evaluation pathway. For continuation, the prescriber must confirm treatment with the requested agent within the past 90 days (sample use is not approvable) and that changing therapy places the patient at risk.

    • For an initial evaluation, document an FDA-labeled indication and route, or an indication supported in compendia, with age support when required.
    • For atopic dermatitis, document the diagnosis and required severity, treatment history, and prior-therapy pathway below.
    • For another FDA-labeled indication, document that the patient's age is within FDA labeling, that use is supported for the patient's age, or that the indication is supported in compendia.
    • Compendia support may include AHFS, DrugDex level 1, 2a, or 2b evidence, or NCCN level 1, 2a, or 2b recommended use.
    • Initial approvals are for 12 months; refer to the quantity-limit criteria when applicable.
    Prior Authorization

    Renewal Prior Authorization Requirements

    Therapy Background

    Cibinqo (abrocitinib) is an oral systemic targeted synthetic small-molecule therapy and oral JAK inhibitor. The policy addresses its use for moderate-to-severe atopic dermatitis and other FDA-labeled or accepted-compendia-supported indications, subject to the applicable clinical, safety, specialist, and utilization requirements.

    Policy Definitions

    Qualifying Moderate-to-Severe Atopic Dermatitis
    Body-surface-area criterionAt least 10% body-surface-area involvement
    Difficult-to-treat sitesHands, feet, face, neck, scalp, genitals/groin, or skin folds
    Validated severity scoresEASI ≥16 or IGA ≥3
    Compendia Support
    AHFSAllowed compendium support
    DrugDexLevel 1, 2a, or 2b evidence
    NCCNLevel 1, 2a, or 2b recommended use

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy requires a qualifying atopic dermatitis or other supported indication plus all applicable safety and utilization requirements.

    Initial therapy requirements

    • Qualifying indication

      • Moderate-to-severe atopic dermatitis

        • Disease-burden criterion

          • The patient has at least 10% body-surface-area involvement; involvement of difficult-to-treat sites; an EASI score of at least 16; or an IGA score of at least 3.BSA ≥10%; EASI ≥16; or IGA ≥3

            Difficult-to-treat sites include the hands, feet, face, neck, scalp, genitals/groin, or skin folds.

        • Prior-treatment or alternative-therapy criterion

    Continuation and Renewal Therapy

    Continuation Criteria

    Continuation and renewal approval requires all of the following conditions.

    Continuation and renewal requirements

    • For continuation of therapy, the prescriber states that the patient has been treated with the requested agent, excluding samples, within the past 90 days and is at risk if therapy is changed.Within the past 90 days

      Starting on samples is not approvable.

    • For renewal, the patient has been previously approved for the requested agent through the plan's prior authorization process and has had clinical benefit with the requested agent.
    • If the patient is age 50 or older and has at least one cardiovascular risk factor, the benefits of treatment outweigh the risks of major adverse cardiovascular events, thrombosis, and all-cause mortality.Age ≥50 with at least one cardiovascular risk factor

    Required Prior Topical Therapy

    StepRequired therapyRequirement or qualifying exception
    1
    Topical corticosteroid
    Tried at least one medium-potency topical corticosteroid for at least 4 weeks with inadequate response; or intolerance/hypersensitivity to one medium-potency topical corticosteroid; or an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids used for atopic dermatitis.
    2
    Topical calcineurin inhibitor
    Tried one topical calcineurin inhibitor, such as pimecrolimus or tacrolimus, for at least 6 weeks with inadequate response; or intolerance/hypersensitivity to one topical calcineurin inhibitor; or an FDA-labeled contraindication to all topical calcineurin inhibitors.
    Alternative pathway
    Biologic or systemic targeted therapy
    Instead of the topical-treatment pathway, medication history may document use of a biologic immunomodulator or systemic targeted synthetic small-molecule drug supported by FDA labeling or compendia for atopic dermatitis. Samples alone do not qualify.

    Cibinqo Quantity Limits

    Cibinqo 50 mg Quantity Limit
    StrengthCibinqo (abrocitinib tablets) 50 mg
    Quantity limit30 tablets
    Day supply30 days
    Cibinqo 100 mg Quantity Limit
    StrengthCibinqo (abrocitinib tablets) 100 mg
    Quantity limit30 tablets
    Day supply30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyCibinqo Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, required pretreatment, safety evaluation, and specialist involvement for Cibinqo.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Documentation ValuesProvider Requirements and Denial RisksTherapy BackgroundPolicy DefinitionsInitial TherapyContinuation and Renewal TherapyRequired Prior Topical TherapyCibinqo Quantity Limits
    At least 10% body-surface-area involvement, difficult-to-treat sites, or IGA ≥3 may also establish disease burden
    Investigator Global Assessment
    ThresholdIGA ≥3
    ConditionQualifies as one disease-burden criterion for moderate-to-severe atopic dermatitis
    Alternative severity criteriaAt least 10% body-surface-area involvement, difficult-to-treat sites, or EASI ≥16 may also establish disease burden
    Topical Corticosteroid Trial
    Required durationAt least 4 weeks
    TherapyAt least one medium-potency topical corticosteroid used for atopic dermatitis
    Response requirementInadequate response, unless qualifying intolerance, hypersensitivity, or FDA-labeled contraindication applies
    Topical Calcineurin Inhibitor Trial
    Required durationAt least 6 weeks
    TherapyOne topical calcineurin inhibitor, such as pimecrolimus or tacrolimus
    Response requirementInadequate response, unless qualifying intolerance, hypersensitivity, or FDA-labeled contraindication applies
    Cardiovascular Risk Review
    PopulationPatients age 50 years or older with at least one cardiovascular risk factor
    Risk factorsCurrent or past smoking, high blood pressure, high cholesterol, diabetes mellitus, prior heart attack, family history of coronary heart disease, or extra-articular rheumatoid arthritis
    Review requirementBenefits must outweigh the risks of major adverse cardiovascular events, thrombosis, and all-cause mortality

    Renewal approval requires all continuation criteria. The patient must have been previously approved through the plan's prior authorization process and must have demonstrated clinical benefit with the requested agent.

    • Patients not previously approved require initial-evaluation review.
    • For patients age 50 or older with at least one cardiovascular risk factor, document that benefits outweigh the risks of major adverse cardiovascular events, thrombosis, and all-cause mortality.
    • Document continued specialist involvement or consultation and compliance with concomitant-therapy requirements.
    • Document that the patient has no FDA-labeled contraindication to the requested agent.
    • Renewal approval is for 12 months; refer to quantity-limit criteria when applicable.
    Billing Rule

    Quantity Limit Applies

    Quantity-limit requirements apply to the requested dose and quantity. The requested quantity is approvable when it does not exceed the program limit, or when an applicable exception is fully supported.

    • If the quantity exceeds the program limit, the requested agent must have no maximum FDA-labeled dose for the indication and there must be support for therapy with a higher dose; OR
    • The quantity must not exceed the maximum FDA-labeled dose and documentation must explain why it cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • Quantity-limit approvals are for 12 months.
    Step Therapy

    Required Atopic Dermatitis Pretreatment

    Document qualifying atopic dermatitis pretreatment. The patient must have tried and had an inadequate response to, or have an intolerance, hypersensitivity, or FDA-labeled contraindication to, the required topical therapies, unless the alternative systemic-treatment pathway applies.

    • At least one medium-potency topical corticosteroid used for AD after at least 4 weeks, with inadequate response; intolerance or hypersensitivity; or an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids used for AD.
    • At least one topical calcineurin inhibitor, such as pimecrolimus or tacrolimus, after at least 6 weeks, with inadequate response; intolerance or hypersensitivity; or an FDA-labeled contraindication to all topical calcineurin inhibitors.
    • As an alternative pathway, medication history excluding sample use may show use of a biologic immunomodulator or systemic targeted synthetic small-molecule drug, such as an oral JAK inhibitor, that is FDA-labeled or compendia-supported for AD.
    Documentation Required

    Atopic Dermatitis Clinical History and Severity

    Document a diagnosis of moderate-to-severe atopic dermatitis and the clinical history supporting severity. The record must show at least one qualifying extent, difficult-to-treat site, or validated severity score.

    • At least 10% body-surface-area involvement; or
    • Involvement of sites difficult to treat with prolonged topical corticosteroid therapy, including hands, feet, face, neck, scalp, genitals/groin, or skin folds; or
    • Eczema Area and Severity Index (EASI) score >=16; or
    • Investigator Global Assessment (IGA) score >=3.
    Documentation Required

    Safety and Specialist Documentation

    Complete required safety and prescriber documentation. The record must address age or compendia support, cardiovascular risk, tuberculosis evaluation, specialist involvement, concomitant immunomodulatory therapy, and contraindications.

    • For an FDA-labeled indication, document that the patient's age is within labeling or that use is supported for the patient's age; alternatively document an indication supported in compendia for the requested agent and route.
    • For a patient age 50 or older with a cardiovascular risk factor—such as current or past smoking, hypertension, hypercholesterolemia, diabetes, history of myocardial infarction, family history of coronary heart disease, or extra-articular rheumatoid arthritis—document that benefits outweigh risks of major adverse cardiovascular events, thrombosis, and all-cause mortality.
    • Document testing for latent tuberculosis; if positive, document that therapy for latent TB has begun.
    • The prescriber must be a specialist in the diagnosis area, such as a dermatologist, allergist, or immunologist, or must have consulted with such a specialist.
    • Document that the patient has no FDA-labeled contraindication to the requested agent.
    Documentation Required

    Combination-Therapy Support

    Combination therapy requires specific support. The requested agent generally must not be used with another immunomodulatory agent unless the prescribing information permits the combination and supporting evidence is submitted.

    • Immunomodulatory agents include TNF inhibitors, JAK inhibitors, and IL-4 inhibitors, among others listed in the Agents NOT to be used Concomitantly table.
    • If combination therapy is proposed, document that the requested agent's prescribing information does not limit use with the other immunomodulatory agent.
    • Submit support for combination therapy, such as clinical trials, phase III studies, or guidelines.
    • If the patient will not use the requested agent with another immunomodulatory agent, document that pathway instead.
    Documentation Required

    Quantity-Limit Exception Documentation

    Requests above the program quantity limit require an exception. Submit documentation establishing either support for a higher dose when no maximum FDA-labeled dose exists, or why the requested quantity cannot be achieved using a lower quantity of a higher strength within the program limit.

    • Document that the requested agent has no maximum FDA-labeled dose for the indication and provide support for higher-dose therapy; or
    • Document that the requested quantity does not exceed the maximum FDA-labeled dose and explain why a lower quantity of a higher strength within the program limit cannot achieve the requested therapy.
    Documentation Required

    Higher-Quantity Exception Support

    Higher-dose or higher-quantity requests must be supported by the applicable exception pathway. The requested quantity must either remain within the program limit or satisfy the FDA-label and clinical-support requirements for an exception.

    • Provide documentation supporting therapy with a higher dose when there is no maximum FDA-labeled dose for the requested indication.
    • When a maximum FDA-labeled dose applies, provide documentation that the request does not exceed that dose and that the requested therapy cannot be achieved with a lower quantity of a higher strength within the program limit.
    Denial Risk

    Indication or Severity Criteria Not Met

    Approval may be denied when the atopic dermatitis indication or severity is not established. The record must support moderate-to-severe AD and at least one qualifying extent, difficult-to-treat site, or severity score, together with the required treatment history or alternative systemic-treatment pathway.

    • Denial risk applies when moderate-to-severe AD is not documented.
    • Denial risk applies when the patient has less than 10% body-surface-area involvement and no qualifying difficult-to-treat sites, EASI score >=16, or IGA score >=3.
    • Denial risk applies when the required medium-potency topical corticosteroid and topical calcineurin-inhibitor history, intolerance, hypersensitivity, or contraindication is not documented and no qualifying biologic or systemic targeted synthetic small-molecule treatment history is provided.
    Denial Risk

    Clinical Safety or Prescriber Requirements Not Met

    Approval may be denied when required safety, prescriber, compendia, or combination-therapy criteria are not met. The request must include the applicable age or compendia support, TB evaluation, specialist involvement, cardiovascular-risk assessment, and evidence supporting any permitted combination therapy.

    • Denial risk applies when the patient's age is outside FDA labeling without age-specific support, or when the indication lacks permitted FDA-label or compendia support.
    • Denial risk applies when latent-TB testing is absent or positive latent TB has not been treated, or when required specialist involvement or consultation is not documented.
    • For patients age 50 or older with cardiovascular risk factors, denial risk applies when the benefit-versus-risk assessment is absent or does not support treatment.
    • Denial risk applies when combination therapy conflicts with prescribing information or lacks submitted clinical-trial, phase III, guideline, or other required support.
    • Denial risk applies when an FDA-labeled contraindication to the requested agent is present.
    Denial Risk

    Quantity-Limit Exception Unsupported

    Excess quantity is not approvable without required support. Requests exceeding the program limit must include documentation for one of the defined quantity-limit exception pathways.

    • Denial risk applies when no support is provided for higher-dose therapy where the requested indication has no maximum FDA-labeled dose.
    • Denial risk applies when the request exceeds the maximum FDA-labeled dose.
    • Denial risk applies when the record does not explain why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    Denial Risk

    Quantity-Limit Exception Not Met

    A quantity-limit exception must satisfy a specified pathway. A request above the program limit is not approvable merely because a higher quantity is requested; it must meet the applicable dose and documentation requirements.

    • The request must either not exceed the program quantity limit, or
    • The agent must have no maximum FDA-labeled dose for the indication with support for higher-dose therapy, or
    • The quantity must not exceed the maximum FDA-labeled dose and must include support that a lower quantity of a higher strength within the program limit cannot achieve treatment.
    Denial Risk

    Contraindicated Concomitant Therapy

    Do not use the requested agent concomitantly with listed immunomodulatory agents. Combination use is not approvable unless the requested agent's prescribing information permits it and supporting evidence is submitted as required by the clinical criteria.

    • Listed agents include Abrilada, Actemra, Adalimumab, Adbry, Amjevita, Anzupgo, Arcalyst, Avsola, Avtozma, Benlysta, Bimzelx, Cibinqo, Cimzia, Cinqair, Cosentyx, Cyltezo, Dupixent, Ebglyss, Enbrel, Entyvio, Exdensur, Fasenra, Hadlima, Hulio, Humira, Hyrimoz, Icotyde, Idacio, Ilaris, Ilumya, Imuldosa, Inflectra, Infliximab, Kevzara, Kineret, Leqselvi, Litfulo, Nemluvio, Nucala, Olumiant, Omlyclo, Omvoh, Opzelura, Orencia, Otezla, Otezla XR, Otulfi, Pyzchiva, Remicade, Renflexis, Rhapsido, Riabni, Rinvoq, Rituxan, Rituxan Hycela, Ruxience, Saphnelo, Selarsdi, Siliq, Simlandi, Simponi, Simponi ARIA, Skyrizi, Sotyktu, Spevigo, Starjemza, Stelara, Steqeyma, Taltz, Tezspire, Tofacitinib, Tofidence, Tremfya, Truxima, Tyenne, Tyruko, Tysabri, Ustekinumab, Velsipity, Wezlana, Xeljanz, Xeljanz XR, Xolair, Yesintek, Yuflyma, Yusimry, Zeposia, and Zymfentra.
    • Combination therapy may be considered only when prescribing information does not limit the combination and clinical trials, phase III studies, guidelines, or other required support are submitted.
  1. Topical-treatment pathway

    • The patient had an inadequate response to at least one medium-potency topical corticosteroid after at least 4 weeks of therapy; has intolerance or hypersensitivity to one such corticosteroid; or has an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids.At least 4 weeks
    • The patient had an inadequate response to one topical calcineurin inhibitor after at least 6 weeks of therapy; has intolerance or hypersensitivity to one topical calcineurin inhibitor; or has an FDA-labeled contraindication to all topical calcineurin inhibitors.At least 6 weeks

      Examples include pimecrolimus and tacrolimus.

  2. Medication history, excluding samples, indicates use of a biologic immunomodulator or systemic targeted synthetic small-molecule drug supported by FDA labeling or compendia for atopic dermatitis.
  3. Other supported indication

    • The patient has another FDA-labeled indication for the requested agent and route of administration.
  4. Age or evidence support

    • For an FDA-labeled indication, the patient's age is within FDA labeling, there is support for use at the patient's age, or the indication is supported in compendia for the requested agent and route of administration.
  5. Safety and utilization requirements

    • If the patient is age 50 or older and has at least one cardiovascular risk factor, the benefits of treatment outweigh the risks of major adverse cardiovascular events, thrombosis, and all-cause mortality.Age ≥50 with at least one cardiovascular risk factor
    • The patient has been tested for latent tuberculosis and, if positive, has begun therapy for latent tuberculosis.
    • The prescriber is a specialist in the patient's diagnosis or has consulted with an appropriate specialist.
    • Concomitant immunomodulator use

      • The patient will not use the requested agent with another immunomodulatory agent.
      • Combination therapy

        • The prescribing information for the requested agent does not limit combination use with another immunomodulatory agent.
        • There is support for the combination, such as submitted clinical trials, phase III studies, or guidelines.
    • The patient does not have any FDA-labeled contraindications to the requested agent.
  6. The prescriber is a specialist in the patient's diagnosis or has consulted with an appropriate specialist, such as a dermatologist, allergist, or immunologist.
  7. Concomitant immunomodulator use

    • The patient will not use the requested agent with another immunomodulatory agent.
    • Combination therapy

      • The prescribing information for the requested agent does not limit combination use with another immunomodulatory agent.
      • There is support for the combination, such as submitted clinical trials, phase III studies, or guidelines.
  8. The patient does not have any FDA-labeled contraindications to the requested agent.
  9. Cibinqo 200 mg Quantity Limit
    StrengthCibinqo (abrocitinib tablets) 200 mg
    Quantity limit30 tablets
    Day supply30 days
    Cibinqo Program Quantity Limit
    Program limitThe requested quantity must not exceed the program quantity limit unless an exception is supported
    Numeric limitThe exact program quantity limit is not stated in this document window
    Exception pathwaysHigher-dose support when no maximum FDA-labeled dose applies, or support that a lower quantity of a higher strength cannot achieve the requested dose within the limit